New research shows that a treatment for retinal vein occlusion yields long-lasting vision gains, with visual acuity remaining significantly above baseline at five years. However, many patients require ...

– RVO is the third indication for Vabysmo, in addition to wet, or neovascular, age-related macular degeneration and diabetic macular edema – – Approval is based on two Phase III studies demonstrating ...

Real-world, 12-month results demonstrated efficacy, safety and durability for faricimab as a treatment for retinal vein ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved Vabysmo ...

FDA Accepts Application for Genentech’s Vabysmo for the Treatment of Retinal Vein Occlusion (RVO) ‒ Acceptance based on two Phase III studies that demonstrated early and sustained vision improvement ...

In both studies, Vabysmo was found to be noninferior to aflibercept, with average vision gains being comparable between the treatment groups. The Food and Drug Administration (FDA) has approved ...

(RTTNews) - Regeneron Pharmaceuticals Inc. (REGN) announced encouraging outcomes from the Phase 3 QUASAR trial, which evaluated the efficacy of EYLEA HD (aflibercept) Injection 8 mg for treating ...

DelveInsight’s “Retinal Vein Occlusion Pipeline Insight 2025” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in the Retinal Vein Occlusion pipeline landscape. It ...

DelveInsight’s “Retinal Vein Occlusion Pipeline Insight 2025” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in the Retinal Vein Occlusion pipeline landscape. It ...

TARRYTOWN, N.Y., June 26, 2015 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that Bayer HealthCare's Japanese subsidiary, Bayer Yakuhin, Ltd., received approval for ...